![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 2, 541-548, May 2003
Department of Physiology and Pharmacology, State University of New
York Downstate Medical Center, Brooklyn, New York
Acute exposure to progesterone or its neurosteroid derivative
allopregnanolone (3
,5
-THP) is anxiolytic, consistent with the
GABA modulatory effects of 3
,5
-THP at the GABAA
receptor. However, continuous exposure to progesterone increases
anxiety in association with increased expression of the
benzodiazepine-insensitive GABAA receptor
4 subunit.
Furthermore, negative mood symptoms and altered GABAA
receptor pharmacology in patients with premenstrual dysphoric disorder
occur in the early luteal phase in association with peak circulating
levels of progesterone and 3
,5
-THP. Because sex differences have
been reported in steroid-regulated anxiety responses, the present study
investigated the role of sex and development in the regulation of
anxiety after short-term exposure to 3
,5
-THP. To this end, we
compared the effects of hormone administration in adult male, adult
female, and juvenile female rats. Increased anxiety in the elevated
plus maze was evident in all groups after 48-h exposure to either
3
,5
-THP or progesterone. At this time point, alterations in the
anxiolytic profile of benzodiazepine agonists and antagonists were also
observed in both adult males and females in the elevated plus maze.
However, sex differences in the acoustic startle response were observed
after short-term hormone treatment such that only female rats displayed
an increased response indicative of higher anxiety levels. These
results suggest that although neurosteroid exposure may influence both
the pharmacological properties of the GABAA receptor and
the manifestation of anxiety in both sexes, the effects of
neurosteroids may be modulated in a sex- and task-specific manner.
This article has been cited by other articles:
![]() |
D. J. Toufexis, C. Davis, A. Hammond, and M. Davis Progesterone Attenuates Corticotropin-Releasing Factor-Enhanced But Not Fear-Potentiated Startle via the Activity of Its Neuroactive Metabolite, Allopregnanolone J. Neurosci., November 10, 2004; 24(45): 10280 - 10287. [Abstract] [Full Text] [PDF] |
||||